Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2025-12-22 00:00:00 ET · period of report 2025-12-18 · accession 0001221355-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-22 | 2025-12-18 | ALLO | Kazam Joshua A | Dir | M - OptEx | $0.00 | +47.7K | 350.8K | +16% | $0 |
| D | 2025-12-22 | 2025-12-18 | ALLO | Kazam Joshua A | Dir | M - OptEx | $0.00 | -47.7K | 47.7K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-18 | M | A | 47,700 | $0.00 | 350,763 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2025-12-18 | M | D | 47,700 | $0.00 | 47,700 | D | — · — to — | 47,700 Common Stock | (F1) On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments. (F2) Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan. (F3) Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. |